Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

bioAffinity Technologies, Inc. (BIAF)

1.83   0.04 (2.23%) 03-24 16:00
Open: 1.9 Pre. Close: 1.79
High: 1.91 Low: 1.75
Volume: 29,626 Market Cap: 15(M)

Technical analysis

as of: 2023-03-24 4:24:23 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.32     One year: 2.68
Support: Support1: 1.5    Support2: 1.24
Resistance: Resistance1: 1.99    Resistance2: 2.29
Pivot: 1.69
Moving Average: MA(5): 1.73     MA(20): 1.69
MA(100): 2.14     MA(250): 0
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 77.7     %D(3): 66.4
RSI: RSI(14): 51.7
52-week: High: 12.81  Low: 1.3
Average Vol(K): 3-Month: 1,352 (K)  10-Days: 21 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BIAF ] has closed below upper band by 7.8%. Bollinger Bands are 63.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.91 - 1.92 1.92 - 1.93
Low: 1.73 - 1.74 1.74 - 1.75
Close: 1.82 - 1.83 1.83 - 1.84

Company Description

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Headline News

Fri, 24 Mar 2023
bioAffinity Technologies to Report Fourth Quarter 2022 Financial ... - Business Wire

Mon, 13 Feb 2023
bioAffinity Technologies Appoints Julie Anne Overton Director of ... - Business Wire

Tue, 24 Jan 2023
bioAffinity Technologies Announces Publication of Results of ... - Business Wire

Wed, 04 Jan 2023
bioAffinity Technologies Announces Notice to Award U.S. Patent ... - Business Wire

Mon, 19 Dec 2022
Argus Research Initiates Equity Research Report Coverage on ... - PR Newswire

Mon, 14 Nov 2022
bioAffinity Technologies Reports Third Quarter 2022 Financial ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. -3 (M)
Shares Float 0 (M)
% Held by Insiders 8.37e+006 (%)
% Held by Institutions 5.34e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -4.22
Profit Margin (%) 0
Operating Margin (%) -124
Return on Assets (ttm) 15.7
Return on Equity (ttm) -26.5
Qtrly Rev. Growth 530.3
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -3.04e+006
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value -0.44
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 99350
Forward Dividend 170840
Dividend Yield 5428960%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.